I can't imagine that there are institutions who
don't know that BTGC exists. You and I found them, and
they have buildings full of people whose job it is to
stay up to date on just about every company out there.
I'm sure they know that this stock is a bargain, and
I kinda think that there may be some other reason
it's not being bought. I just have no idea what that
reason could possibly be. Chalk it up to them not being
as smart as us, I guess. I know one thing for sure.
I'm not selling BTGC for a long, long while. The math
doesn't lie, and the share price will always catch up
with the earnings, though some issues take a little
longer that others.
I was glad to hear them get hit a number of times
with questions about getting out and telling their
story. They need to sell themselves to more
brokers/analysts and attract more institutional ownership of the
stock. To date though I must say that their PR is very
lacking. The fundamentals are there but that won't do them
any good if institutions don't know they exist.
I was very surprised (pleasantly, I should say)
that during CC, the company repeatedly assured
audience of EPS 25% growth rate not only for the next
couple of years, but for the next 5-7 years. They even
indicated that this 25% growth rate was based on the worst
case scenario. Of course, there is a question whehter
you believe what they say. Otherwise, who can ask
anything more? Especially for a biotech company. Looking
back their history, it seems that they do deliver what
they said. Based on the minimum projected ESP for 1999
(.45), the stock's fair value should be at least $11.
They stated that they are insuring 25% EPS growth
over the next few years. Yes, Fass used the word
"insure". Oxandrin should be used for more than AIDS by mid
year (wound care). Biotropin should be over $25
million in '99. Have over $70 million cash now looking at
acquisitions. Tax rate was reduced due to R&D tax credits, will
be up in '99 to around 29% from 28.3% in '98. Stated
that expenses will grow less than earnings. Will be at
Alex Brown conference in may and hope to be at Goldman
Sachs conference in June. They will not be buying back
any shares. And they concluded by stating that
revenues will exceed $100 million in '99 and EPS will be
at ;east 45 cents a share.
You should have listened longer. A lot of
positive comments were made for the medium and long term
investor. Call today by 5 PM and let me know if you do not
No matter how you slice it this stock is
under-valued, big time. The low exposure to the investment
community is being addressed. They have been meeting
privately with other brokerage houses besides ML and
thought it was a good idea (when suggested by a caller)
to hold breakfast meetings with analysts to tell
Does everyone agree that at these
prices BTGC is a screaming buy?
Yes, then tell a
Enjoyed your message so much I think it should be
emailed to BTGC's Investor Relations.
in this stock at 16 for over two years. Won't sell
again till reaches double so all you shorters,
doomsdayers & the like can take a hike. Long on BTGC!
It looks like all of BTGC's sales growth came
from Oxandrin. Total sales increased to 68 from 54 =
14 mil, Oxandrin 41 from 28 = 13mil. So there is
virtually no increase in sales of other products. I'm long
at BTGC and I'm not going to hedge my position in it
in near future. But I personally think that more
attention has to given to R&D and promotion of other
products. BTGC's sales are too leveraged with Oxandrin now,
I don't mean that it is bad in any way.
I only listened for 5 mins. But I hear a common
tread from many securities people asking questions.
WHAT ARE YOU GOING TO DO FOR THE INVESTORS!!!. And all
Fiss said is grow the company @ 25%. It almost seemed
to me that the securities people were not to happy
to the answer they were getting about, aquistions
and royalty Fee's. All the people wanted was a good
number a target number. But all Fiss would say is that
they could be Subtaintially greater. This guy just
kept dodging the questions. He is a walfler and would
not comment. I hate people like that. Put your balls
on the line. Give me your feedback
I read the press release and
although the numbers were not great they are in line with
the September 1998 quarter. The decrease in sales vs.
the September 1998 quarter was probably due to the
timing of orders as explained in past quarterly reports
and contract fees.
What's the problem?
Problem A - The press release is not informative. BTG
should be presenting virtually the same information in
the press release as they do in the distributed
quarterly earnings report to shareholders'.
1.We want to increase the demand for the stock by
having non-shareholders buy-it. 2. We, the shareholders'
want to understand where the future growth of this
company will come from and why we should continue to hold
it. 3. Other companies are getting away from mailings
because of the cost, the availability of the information
on-line and timeliness.
Problem B - No comments on
the current quarter, all comments are for the year -
it looks like BTG is hiding something. In fact,
income is up ( and I believe sales, too) over the fourth
quarter of last year.
Solution - read press
releases of other companies; have your external investor
relations help write the release, or (more common) hire the
If anybody else agrees with me, any additional
messages may drive my point home.
Let's get going
and improve how BTG is being presented!